---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-010792"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:34:55.103830+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040

## Summary
- EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.
- European patent protection through at least December 2040, with potential SPC extension beyond.
- Patent also covers active metabolites OR1896/OR1855 and combination with other cardiovascular drugs.
- Builds on existing U.S. and Canada patents; supports Phase 3 LEVEL-2 study initiation expected this year.

## SEC filing metadata
- accession: 0001654954-25-010792
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495425010792/0001654954-25-010792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495425010792/tennx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-010792
- JSON: https://secwatch.observer/filing/0001654954-25-010792.json
- Plain text: https://secwatch.observer/filing/0001654954-25-010792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.